Pioneering diagnostics

VIDAS® range

VIDAS® is the most widely used immunoassay system in clinical laboratories worldwide. Its robust design and single-test concept make it well-adapted to all types of laboratories.

  • VIDAS® and its compact version, MINI VIDAS®, have an installed base of approximately 34,500 systems worldwide, including 29,500 in clinical laboratories.
  • VIDAS® 3 brings new features and enhanced automation. This new generation, was developed with healthcare professionals to meet their needs in a changing technical, organizational and regulatory environment. It provides:
    • greater autonomy: tests can be performed on demand, 24 hours a day and seven days a week,
    • a tailored solution with an intuitive touch screen interface,
    • enhanced automation including an integrated pipetting system,
    • improved traceability.

The technology

  • VIDAS® uses ELFA technology (Enzyme Linked Fluorescent Assay) and is based on the single-test concept.
    • VIDAS® changed the field of immunoassays, offering laboratories a simple and robust technique that delivers reliable and rapid results.
    • It can conduct all steps of biological testing automatically and detect and/or quantify:
      • antigens or toxins showing a viral or bacterial infection,
      • antibodies quantifying the immune response to infection,
      • markers for diseases such as cancer, metabolic diseases or hormonal disorders.
    • Tests can be carried out individually or in series.
    • Drawing on its expertise acquired in the field of clinical diagnostics, biomérieux has adapted the VIDAS® technology to serve the needs of industrial microbiological control laboratories in the agri-food sector.

bioMérieux's offering

The VIDAS® menu comprises over 100 parameters, covering a wide range of human pathologies with high medical-value tests to target infectious diseases, in particular sepsis and cardiovascular diseases.

 

The application of bacteriophage technology

to immunoassays 

 

  • Bacteriophages are viruses programmed exclusively to identify and infect a specific type of bacteria. 
  • Bacteriophage technology simulates the virus’ attack on the bacteria: the proteins recognize the targeted bacteria and bind to it.
  • bioMérieux was the first to use bacteriophage proteins for the targeted capture and detection of bacteria in a sample for microbiological control.

    This technology, integrated in our VIDAS® UP tests, brings:

  • detection tests with unrivalled performance levels (sensitivity, specificity, ease of use),
  • results obtained within 24 hours, instead of several days as is the case with reference methods.